IRVINE, Calif., Nov. 7, 2011 /PRNewswire/ -- Syneron Medical Ltd.
(NASDAQ: ELOS), www.syneron.com, the global leader in medical
aesthetic products and technology featured a live demonstration of
their latest technology, ePrime, on the October 27, 2011 segment of The Doctors.
The audience and viewers of The Doctors witnessed
first-hand the ePrime procedure and the immediate post treatment
results.
(Logo:
http://photos.prnewswire.com/prnh/20111107/NY99332LOGO )
ePrime stands as the only energy-based dermal remodeling device
that delivers energy directly to the dermis boosting the skin's
natural production of collagen, elastin and hyaluronic acid.
"ePrime is a revolutionary new technology in facial aesthetics that
delivers energy directly into the skin to produce a
three-dimensional improvement to the topography and volume of the
skin," said Mitch Chasin, M.D.,
Cosmetic Laser Specialist and Medical Director at Reflections
Center for Skin and Body in Livingston and Bridgewater, New Jersey. "What sets the
ePrime apart clinically from other energy-based devices is that it
not only stimulates the production of new collagen, which is
standard in many energy-based devices and even with popular
topicals, but it has also been clinically proven to stimulate
elastin and hyaluronic acid reproduction – the trinity of natural
youth allowing skin to not only look younger, but behave younger
too."
For the first time ePrime's proprietary Intelligent Feedback
Systems™ (IFS), which measures temperature in real time, allows
practitioners to adjust power levels to safely and effectively meet
the needs of different skin conditions and all skin types.
This single treatment procedure takes less than an hour to
perform under local anesthetic allowing patients to drive home
safely post-treatment and return to normal activities within 24
hours.
"At Syneron we work diligently alongside our physician partners
to remain at the forefront of cutting-edge applications," said
Louis P. Scafuri, Chief Executive
Officer of Syneron Medical and Candela Corporation. "ePrime
exemplifies our commitment to innovation as it introduces a new
paradigm in controlled precision delivery of energy to a specific
target which we believe will spark new and exciting advancements in
the field of medical aesthetics for both face and body."
To view The Doctor segment featuring ePrime –
http://www.youtube.com/watch?v=V0wYdPQ2GDc
For more information about ePrime and to locate a physician in
your area, visit www.syneron.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology,
real science and real results – is the leading global aesthetic
device company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables
physicians to provide advanced solutions for a broad range of
medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite.
The Company sells its products under two distinct brands,
Syneron and Candela. The Company's aspiration and commitment
to innovation expands Syneron's offering beyond medical device into
the largest in-demand applications in beauty - skin lightening.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
SOURCE Syneron Medical Ltd.